TD Cowen cuts price targets on Abbott and Symbotic
TD Cowen lowered its Abbott price target to $118 from $135 and Symbotic's to $70 from $75, while keeping its Buy rating on Symbotic, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Dow Jones Newswires reports that TD Cowen cut its Abbott Laboratories price target to $118 per share from $135. The firm also lowered its Symbotic target to $70 from $75, while maintaining a Buy rating on the stock.
The two changes concern separate companies and are not linked, so they are best read individually.
why it matters
Adjustments like these usually reflect an analyst revising expectations for a single stock and rarely move the broader market on their own. For investors in healthcare and robotics, overall earnings trends matter more than one brokerage's decision.
tags
instruments
sources
- Abbott Labs Price Target Cut to $118.00/Share From $135.00 by TD Cowen — Dow Jones Newswires, 22 October 2026 at 13:41 UTC
- Symbotic Price Target Cut to $70.00/Share From $75.00 by TD Cowen — Dow Jones Newswires, 22 October 2026 at 13:56 UTC
- Abbott Labs Price Target Cut to $118.00/Share From $120.00 by JP Morgan — Dow Jones Newswires, 22 October 2026 at 14:06 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗